We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
Read MoreHide Full Article
Shares of Agenus Inc. (AGEN - Free Report) gained 10.1%, following the company’s third-quarter results. The company reported third-quarter 2018 loss of 29 cents per share, wider than the Zacks Consensus Estimate of loss of 25 cents but narrower than the year-ago loss of 37 cents.
The company generated revenues of $13 million, which include milestone achievements and non-cash royalties earned, compared with $3.3 million in the year-ago quarter. Revenues beat the Zacks Consensus Estimate of $11 million.
So far this year, shares of Agenus have declined 35.9% compared with the industry’s decrease of 13.5%.
Quarterly Highlights
Research and development (R&D) expenses increased 15.7% to $29.8 million. General and administrative expenses increased 14.3% to $9.2 million.
Pipeline Update
Agenus is a clinical-stage immuno-oncology company with a comprehensive portfolio, consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms.
Lead clinical-stage antibodies, CTLA-4 and PD-1 antibodies are progressing well. PD-1 agent, AGEN2034 showed a clinical benefit of 68% in evaluable patients with metastatic or locally advanced solid tumors. The company recently reported that out of the 130 patients treated with CTLA-4 and PD-1 antibodies, more than 60% have shown clinical benefit. The company targets a biologics license application (BLA) filing as early as 2020.
In September 2018, the company announced the closing of its non-dilutive royalty transaction with XOMA Corp. (XOMA - Free Report) , whereby the latter purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte (INCY - Free Report) and Merck (MRK - Free Report) .
Earlier, Agenus received a cash milestone from Incyte for the initiation of a phase I trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Per the terms, Agenus received a $5-million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte.
In August 2018, Agenus received a $4-million milestone payment from Merck for the initiation of a phase I trial on an undisclosed antibody candidate.
The company filed four investigational new drugs (INDs) in 2018. Two additional INDs will be filed by the end of the year.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
Shares of Agenus Inc. (AGEN - Free Report) gained 10.1%, following the company’s third-quarter results. The company reported third-quarter 2018 loss of 29 cents per share, wider than the Zacks Consensus Estimate of loss of 25 cents but narrower than the year-ago loss of 37 cents.
The company generated revenues of $13 million, which include milestone achievements and non-cash royalties earned, compared with $3.3 million in the year-ago quarter. Revenues beat the Zacks Consensus Estimate of $11 million.
So far this year, shares of Agenus have declined 35.9% compared with the industry’s decrease of 13.5%.
Quarterly Highlights
Research and development (R&D) expenses increased 15.7% to $29.8 million. General and administrative expenses increased 14.3% to $9.2 million.
Pipeline Update
Agenus is a clinical-stage immuno-oncology company with a comprehensive portfolio, consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms.
Lead clinical-stage antibodies, CTLA-4 and PD-1 antibodies are progressing well. PD-1 agent, AGEN2034 showed a clinical benefit of 68% in evaluable patients with metastatic or locally advanced solid tumors. The company recently reported that out of the 130 patients treated with CTLA-4 and PD-1 antibodies, more than 60% have shown clinical benefit. The company targets a biologics license application (BLA) filing as early as 2020.
In September 2018, the company announced the closing of its non-dilutive royalty transaction with XOMA Corp. (XOMA - Free Report) , whereby the latter purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte (INCY - Free Report) and Merck (MRK - Free Report) .
Earlier, Agenus received a cash milestone from Incyte for the initiation of a phase I trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Per the terms, Agenus received a $5-million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte.
In August 2018, Agenus received a $4-million milestone payment from Merck for the initiation of a phase I trial on an undisclosed antibody candidate.
The company filed four investigational new drugs (INDs) in 2018. Two additional INDs will be filed by the end of the year.
Zacks Rank
Agenus currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>